Cargando…

The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors

Essential thrombocythemia is a rare hematological malignancy with good overall survival, but moderate to high risk of developing arterial or venous thrombosis lifelong. Different thrombotic risk scores for patients with essential thrombocythemia have been proposed, but only one of them (the IPSET-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancuso, Salvatrice, Accurso, Vincenzo, Santoro, Marco, Raso, Simona, Contrino, Angelo Davide, Perez, Alessandro, Di Piazza, Florinda, Florena, Ada Maria, Russo, Antonio, Siragusa, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139859/
https://www.ncbi.nlm.nih.gov/pubmed/32280344
http://dx.doi.org/10.1155/2020/9124821
_version_ 1783518862972551168
author Mancuso, Salvatrice
Accurso, Vincenzo
Santoro, Marco
Raso, Simona
Contrino, Angelo Davide
Perez, Alessandro
Di Piazza, Florinda
Florena, Ada Maria
Russo, Antonio
Siragusa, Sergio
author_facet Mancuso, Salvatrice
Accurso, Vincenzo
Santoro, Marco
Raso, Simona
Contrino, Angelo Davide
Perez, Alessandro
Di Piazza, Florinda
Florena, Ada Maria
Russo, Antonio
Siragusa, Sergio
author_sort Mancuso, Salvatrice
collection PubMed
description Essential thrombocythemia is a rare hematological malignancy with good overall survival, but moderate to high risk of developing arterial or venous thrombosis lifelong. Different thrombotic risk scores for patients with essential thrombocythemia have been proposed, but only one of them (the IPSET-t scoring system) takes into account the classical cardiovascular risk factors as one of the scoring items. Currently, in clinical practice, the presence of cardiovascular risk factors in patients with diagnosis of ET rarely determines the decision to initiate cytoreductive therapies. In our study, we compared different risk models to estimate the thrombotic risk of 233 ET patients and the role of specific driver mutations and evaluated the impact that conventional cardiovascular risk factors (hypertension, cigarette smoking, diabetes, obesity, and dyslipidaemia) have on thrombotic risk in patients with ET. Perspective studies conducted on a polycentric large cohort of patients should be conducted to estimate the impact of cardiovascular risk factors in determining thrombosis in ET patients, evaluating the opportunity of initiating a cytoreductive therapy in patients with cardiovascular risk factors, even if classified into low to moderate risk groups according to other scoring systems.
format Online
Article
Text
id pubmed-7139859
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-71398592020-04-10 The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors Mancuso, Salvatrice Accurso, Vincenzo Santoro, Marco Raso, Simona Contrino, Angelo Davide Perez, Alessandro Di Piazza, Florinda Florena, Ada Maria Russo, Antonio Siragusa, Sergio Adv Hematol Research Article Essential thrombocythemia is a rare hematological malignancy with good overall survival, but moderate to high risk of developing arterial or venous thrombosis lifelong. Different thrombotic risk scores for patients with essential thrombocythemia have been proposed, but only one of them (the IPSET-t scoring system) takes into account the classical cardiovascular risk factors as one of the scoring items. Currently, in clinical practice, the presence of cardiovascular risk factors in patients with diagnosis of ET rarely determines the decision to initiate cytoreductive therapies. In our study, we compared different risk models to estimate the thrombotic risk of 233 ET patients and the role of specific driver mutations and evaluated the impact that conventional cardiovascular risk factors (hypertension, cigarette smoking, diabetes, obesity, and dyslipidaemia) have on thrombotic risk in patients with ET. Perspective studies conducted on a polycentric large cohort of patients should be conducted to estimate the impact of cardiovascular risk factors in determining thrombosis in ET patients, evaluating the opportunity of initiating a cytoreductive therapy in patients with cardiovascular risk factors, even if classified into low to moderate risk groups according to other scoring systems. Hindawi 2020-03-27 /pmc/articles/PMC7139859/ /pubmed/32280344 http://dx.doi.org/10.1155/2020/9124821 Text en Copyright © 2020 Salvatrice Mancuso et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mancuso, Salvatrice
Accurso, Vincenzo
Santoro, Marco
Raso, Simona
Contrino, Angelo Davide
Perez, Alessandro
Di Piazza, Florinda
Florena, Ada Maria
Russo, Antonio
Siragusa, Sergio
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
title The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
title_full The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
title_fullStr The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
title_full_unstemmed The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
title_short The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
title_sort essential thrombocythemia, thrombotic risk stratification, and cardiovascular risk factors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139859/
https://www.ncbi.nlm.nih.gov/pubmed/32280344
http://dx.doi.org/10.1155/2020/9124821
work_keys_str_mv AT mancusosalvatrice theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT accursovincenzo theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT santoromarco theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT rasosimona theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT contrinoangelodavide theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT perezalessandro theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT dipiazzaflorinda theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT florenaadamaria theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT russoantonio theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT siragusasergio theessentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT mancusosalvatrice essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT accursovincenzo essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT santoromarco essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT rasosimona essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT contrinoangelodavide essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT perezalessandro essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT dipiazzaflorinda essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT florenaadamaria essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT russoantonio essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors
AT siragusasergio essentialthrombocythemiathromboticriskstratificationandcardiovascularriskfactors